Literature DB >> 3201536

Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism.

R J Guttendorf1, P J Wedlund, J Blake, S L Chang.   

Abstract

Identifying individuals with a deficient capacity for oxidative drug metabolism is of increasing clinical importance. Dextromethorphan (DM) is gaining wide acceptance as a probe drug to characterize individual expression of a specific cytochrome P-450 isozyme. The thin-layer chromatography (TLC) technique described in the present study is a rapid and inexpensive alternative to the methods currently available for assessing the urinary metabolic profile of DM. Sixty-five healthy volunteers participated in the study by ingesting 213 mmol DM and collecting all urine for the ensuing 8 h. Urine samples were analyzed by TLC and high-performance liquid chromatography (HPLC) after treatment with beta-glucuronidase. Based on the relative color intensities of DM and its O-demethylated metabolite, dextrorphan, the TLC analysis provided an accurate phenotype assessment. A greater intensity of the parent drug relative to the metabolite indicates a poor metabolizer phenotype whereas a reversed relative intensity indicates the extensive metabolizer phenotype. The phenotype assignments made by TLC were verified by comparison with the quantitative results (based on metabolic ratios) obtained from HPLC analysis. Complete agreement was found between the two methods. The routine implementation of phenotype determination into clinical protocols can be realized with this facile TLC technique.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3201536     DOI: 10.1097/00007691-198804000-00021

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats.

Authors:  M Dostalek; E Hadasova; M Hanesova; J Pistovcakova; A Sulcova; J Jurica; J Tomandl; I Linhart
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

2.  Lack of association between glucose-6-phosphate dehydrogenase deficiency and dextromethorphan O-demethylation polymorphism.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.

Authors:  L B Anthony; T J Boeve; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Authors:  R J Guttendorf; M Britto; R A Blouin; T S Foster; W John; K A Pittman; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.